Strong progress towards commercialisation of LungLB® LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides an update on its operational progress made since the release of its interim results announcement. The Company has continued to execute on the commercial proof of concept of LungLB® and to explore opportunities for a suitable […]
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: For further information please contact: LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO via investors@lunglifeai.com Click here to download […]
LungLife AI licensure/accreditation information posted here.